Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients

Jennette, 2013, 2012 revised international chapel hill consensus conference nomenclature of vasculitides, Arthritis Rheum, 65, 1, 10.1002/art.37715 Hatemi, 2020, One year in review 2020: behçet's syndrome, Clin Exp Rheumatol, 127, 3, 10.55563/clinexprheumatol/lnvc9k Davatchi, 2017, Behcet's disease: epidemiology, clinical manifestations, and diagnosis, Expert Rev Clin Immunol, 13, 57, 10.1080/1744666X.2016.1205486 Taylor, 2011, Behcet disease: visual prognosis and factors influencing the development of visual loss, Am J Ophthalmol, 152, 1059, 10.1016/j.ajo.2011.05.032 Tugal-Tutkun, 2004, Uveitis in Behçet disease: an analysis of 880 patients, Am J Ophthalmol, 138, 373, 10.1016/j.ajo.2004.03.022 Martínez-Berriotxoa, 2012, Uveitis: diagnostic approach, Rev Clin Esp, 212, 442, 10.1016/j.rce.2011.12.004 Jabs, 2005, Standardization of uveitis nomenclature (SUN) working group. standardization of uveítis nomenclature for reporting clinical data. results of the first international workshop, Am J Ophthalmol, 140, 509, 10.1016/j.ajo.2005.03.057 Ozyazgan, 2015, Ocular involvement of Behcet's syndrome: a comprehensive review, Clin Rev Allergy Immunol, 49, 298, 10.1007/s12016-014-8425-z Ozdal, 2002, Posterior segment involvement in ocular Behcet's disease, Eur J Ophthalmol, 12, 424, 10.1177/112067210201200514 Rotsos, 2008, Cystoid macular edema, Clin Ophthalmol, 2, 919, 10.2147/OPTH.S4033 Bringmann, 2004, Pathomechanisms of cystoid macular edema, Ophthalmic Res, 36, 241, 10.1159/000081203 Hatemi, 2018, 2018, update of the Eular recommendations for the management of Behçet's syndrome, Ann Rheum Dis, 77, 808 Urruticoechea-Arana, 2019, Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet's disease associated uveitis: a systematic review, Rheumatol Int, 39, 47, 10.1007/s00296-018-4193-z Martín-Varillas, 2018, Successful optimization of adalimumab therapy in refractory Uveitis due to Behçet's disease, Ophthalmology, 125, 1444, 10.1016/j.ophtha.2018.02.020 Ksiaa, 2019, Eye and Behçet's disease, J Fr Ophtalmol, 42, 626, 10.1016/j.jfo.2018.09.027 Hirano, 2012, A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab, Mod Rheumatol, 22, 298, 10.3109/s10165-011-0497-5 Desbois, 2018, Ocular manifestations in Behçet's disease, Rev Med Interne, 39, 738, 10.1016/j.revmed.2018.02.022 Lopalco, 2017, IL-6 blockade in the management of non-infectious uveitis, Clin Rheumatol, 36, 1459, 10.1007/s10067-017-3672-z Liu, 2020, Clinical features of patients with Behçet's uveitis, Zhonghua Yan Ke Za Zhi, 56, 217 Thomas, 2019, Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics, Curr Opin Ophtalmol, 30, 138, 10.1097/ICU.0000000000000562 Tosi, 2020, Efficacy of monoclonal anti-tumour necrosis factor- α antibodies in uveítis macular edema, Clin Exp Rheumatol, 38, 621 Kunimi, 2022, Anti-TNF- α Therapy for refractory uveitis associated with Behçet's syndrome and sarcoidosis: a single center study of 131 patients, Ocul Immunol Inflamm, 30, 223, 10.1080/09273948.2020.1791346 Atienza-Mateo, 2019, Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet's disease: national multicenter study of 177 cases, Arthritis Rheumatol, 71, 2081, 10.1002/art.41026 Vegas-Revenga, 2019, Anti-IL6-Receptor tocilizumab in refractory and noninfectious Uveitic cystoid macular Edema: multicenter study of 25 patiens, Am J Ophthalmol, 200, 85, 10.1016/j.ajo.2018.12.019 Adán, 2013, Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefe's, Arch Clin Exp Ophthalmol, 251, 2627, 10.1007/s00417-013-2436-y Atienza-Mateo, 2018, Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study, Rheumatology (Oxford), 57, 856, 10.1093/rheumatology/kex480 Atienza-Mateo, 2022, Utility of tocilizumab in autoimmune eye diseases, Expert Opin Biol Ther, 20, 1 Papo, 2014, Tocilizumab in severe and refractory non-infectious uveitis, Clin Exp Rheumatol, 32, S75 Santos-Gómez, 2016, The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study, Clin Exp Rheumatol, 34, S34 Takeuchi, 2019, Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: a multicenter study, Medicine (Baltimore), 98, e14668, 10.1097/MD.0000000000014668 Silvestri, 2020, Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome, Inflammopharmacology, 28, 711, 10.1007/s10787-020-00697-4 Fabiani, 2019, Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients, Clin Rheumatol, 38, 407, 10.1007/s10067-018-4228-6 Park, 2021, The effect of adalimumab in Korean patients with refractory noninfectious uveitis, Yonsei Med J, 62, 177, 10.3349/ymj.2021.62.2.177 Leclercq, 2022, Anti–Tumor necrosis factor α versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French uveitis network, Ophthalmology, 129, 520, 10.1016/j.ophtha.2021.11.013 Atienza-Mateo, 2021, Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes, Clin Exp Rheumatol, 132, 37, 10.55563/clinexprheumatol/9ipkcs Weichsler, 1990, Criteria for diagnosis of Behçet's disease. International study group for Behçet's disease, Lancet (British Ed.), 335, 1078 Levenson, 1990, Visual acuity Nussenblatt, 1985, Standardization of vitreal inflammatory activity in intermediate and posterior uveitis, Ophthalmology, 92, 467, 10.1016/S0161-6420(85)34001-0 Valenzuela, 2020, Pharmacological strategies for the treatment of non-infectious uveitis. A minireview, Front Pharmacol, 11, 655, 10.3389/fphar.2020.00655 Mesquida, 2018, Twenty-four-month follow-up of tocilizumab therapy for refractory uveitis-related macular edema, Retina, 38, 1361, 10.1097/IAE.0000000000001690 Leclercq, 2020, Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis, J Autoimmun, 113, 10.1016/j.jaut.2020.102481 Touhami, 2019, Expert opinion on the use of biological therapy in non-infectious uveitis, Expert Opin Biol Ther, 19, 477, 10.1080/14712598.2019.1595578 ClinicalTrials.gov NCT02929251 randomized trial comparing efficacy of adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis (RUBI). Fabiani, 2017, Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study, Clin Rheumatol, 36, 191, 10.1007/s10067-016-3506-4